FDA Warning Letter highlights risks of using AI in drug manufacturing | DLA Piper
However, this Warning Letter demonstrates the risks of overreliance on AI , which can lead to broad quality system failures. AI adoption does not ...
Read the original at DLA Piper ↗
- Topics
- HealthcareManufacturing & Robotics
- Mentions
- FDA
- Tracked via
- “AI Risks”
Same story, other outlets
- FDA Warning Letter highlights risks of using AI in drug manufacturing | DLA Piper - JD Supra JD Supra · Apr 24, 2026